<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "https://jats.nlm.nih.gov/archiving/1.3/JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" dtd-version="1.3" article-type="research-article" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">journal-of-clinical-obstetrics-and-gynecology-research</journal-id>
      <journal-title-group>
        <journal-title>Journal of Clinical Obstetrics and Gynecology Research</journal-title>
      </journal-title-group>
      <issn publication-format="electronic">2766-2756</issn>
      <publisher>
        <publisher-name>Directive Publications</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="doi">10.52338/jocogr.2026.5815</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Multimodal High-Intensity Electromagnetic Therapy Using The Heager GmbH Alfonse System For Pelvic Floor Dysfunction, Stress Urinary Incontinence, Erectile Dysfunction, And Core Muscle Rehabilitation: A Prospective Multicenter Clinical, Sonographic, Histopathological, And Molecular Study</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Almeida</surname>
            <given-names>Diego F.</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guzmán</surname>
            <given-names>Mateo R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Vargas</surname>
            <given-names>Andrés I.</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Beltrán</surname>
            <given-names>Laura N.</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Montero</surname>
            <given-names>Ricardo E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">5</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Clinton</surname>
            <given-names>Smith</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">6</xref>
        </contrib>
        <aff id="aff1"><label>1</label>Department of Physical Medicine and Rehabilitation, Federal University of Rio Grande</aff>
        <aff id="aff2"><label>2</label>Department of Urology and Men's Health, Universidad Nacional de Colombia</aff>
        <aff id="aff3"><label>3</label>Department of Pelvic Floor Rehabilitation, Hospital Clínico de Santiago</aff>
        <aff id="aff4"><label>4</label>Department of Gynecology and Functional Rehabilitation, Universidad de Buenos Aires</aff>
        <aff id="aff5"><label>5</label>Department of Biomedical Engineering and Electrophysiology, São Paulo Institute of Medical Technology</aff>
        <aff id="aff6"><label>6</label>Leoma LLC, Boise, ID</aff>
      </contrib-group>
      <pub-date publication-format="electronic" date-type="pub" iso-8601-date="2026-06-17">
        <day>17</day>
        <month>06</month>
        <year>2026</year>
      </pub-date>
      <volume>17</volume>
      <issue>1</issue>
      <history>
        <date date-type="received" iso-8601-date="2026-05-20">
          <day>20</day>
          <month>05</month>
          <year>2026</year>
        </date>
        <date date-type="accepted" iso-8601-date="2026-06-05">
          <day>05</day>
          <month>06</month>
          <year>2026</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2026 The Author(s). Published by Directive Publications.</copyright-statement>
        <copyright-year>2026</copyright-year>
        <copyright-holder>The Author(s)</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by/4.0/">
          <ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
          <license-p>This is an open access article distributed under the terms of the CC BY 4.0 licence (https://creativecommons.org/licenses/by/4.0/).</license-p>
        </license>
      </permissions>
      <self-uri content-type="html" xlink:href="https://directivepublications.org/journal-of-clinical-obstetrics-and-gynecology-research/multimodal-high-intensity-electromagnetic-therapy-using-the-heager-gmbh-alfonse-system-for-pelvic-floor-dysfunction"/>
      <self-uri content-type="pdf" xlink:href="https://directivepublications.org/pdf/985/multimodal-high-intensity-electromagnetic-therapy-using-the-heager-gmbh-alfonse-system-for-pelvic-floor-dysfunction-stress-urinary-incontinence-erectile-dysfunction-and-core-muscle-rehabilitation-a-prospective-multicenter-clinical-sonographic-histopathological-and-molecular-study.pdf"/>
      <abstract>
        <p>Background: Pelvic floor dysfunction, stress urinary incontinence (SUI), urge urinary symptoms, erectile dysfunction (ED), chronic pelvic instability, and weakened core musculature are highly prevalent conditions associated with aging, childbirth, obesity, sedentary lifestyle, and neuromuscular deconditioning. High-intensity electromagnetic stimulation has emerged as a non-invasive therapeutic modality capable of inducing supramaximal muscle contractions and neuromuscular activation without direct skin contact. Objective: This multicenter prospective study evaluated the safety, tolerability, clinical response, sonographic changes, histopathological findings, and molecular remodeling patterns associated with the Heager GmbH Alfonse electromagnetic therapy system, a multimodal platform incorporating three independent electromagnetic field generators intended to target pelvic floor musculature, cavernous/perineal musculature, and abdominal/core musculature. Methods: A prospective multicenter clinical cohort study was conducted across rehabilitation, urogynecology, and men's health centers in South America between 2022 and 2025. One hundred adult participants underwent a structured treatment protocol. The platform incorporates three independent generators with nominal field capacities of 3 Tesla, 2.5 Tesla, and 1.5 Tesla. Clinical outcomes included ICIQ-SF, IIEF-5, pelvic floor strength grading, pain scores, and patient-reported global improvement. Imaging and biological analyses included transperineal ultrasonography, muscle thickness evaluation, histopathology, and immunohistochemical markers including alpha-SMA and VEGF. Results: Substantial clinical improvement was observed across multiple outcome domains. Mean ICIQ-SF scores improved significantly in patients with urinary symptoms, while male participants with erectile dysfunction demonstrated clinically meaningful increases in IIEF-5 scores. Sonographic assessment demonstrated increased pelvic floor muscle density and improved structural organization. Histopathology demonstrated improved muscle fiber alignment, reduced interstitial disorganization, increased alpha-SMA expression, and enhanced VEGF-associated vascular signaling. No serious adverse events were observed. Conclusion: The Heager GmbH Alfonse multimodal electromagnetic therapy system demonstrated encouraging short-term clinical, sonographic, and biological outcomes in pelvic floor rehabilitation, urinary symptom management, erectile dysfunction support, and core muscle strengthening. These findings support further randomized sham-controlled studies with longer-term follow-up.</p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <kwd>Erectile dysfunction</kwd>
        <kwd>High-intensity electromagnetic therapy</kwd>
        <kwd>Muscle remodeling</kwd>
        <kwd>Neuromuscular stimulation</kwd>
        <kwd>Pelvic floor dysfunction</kwd>
        <kwd>Pelvic rehabilitation</kwd>
        <kwd>Stress urinary incontinence</kwd>
        <kwd>supramaximal contraction therapy</kwd>
        <kwd>Transperineal ultrasound</kwd>
        <kwd>VEGF</kwd>
        <kwd>α-SMA</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec id="introduction">
      <label>1</label>
      <title>Introduction</title>
      <p>Pelvic floor dysfunction encompasses a broad spectrum of disorders affecting urinary continence, pelvic organ support, bowel function, sexual function, and core stability. These disorders affect both women and men and are frequently associated with childbirth, menopause, aging, obesity, neurologic disease, chronic straining, pelvic surgery, sedentary lifestyle, and generalized muscular deconditioning.</p>
      <p>Stress urinary incontinence remains one of the most common pelvic floor disorders in women and substantially affects quality of life, emotional wellbeing, social participation, sexual confidence, and physical activity. Similarly, erectile dysfunction in men is a multifactorial disorder involving vascular, neurologic, hormonal, psychogenic, and muscular components. Increasing evidence suggests that pelvic floor musculature, perineal support structures, and cavernous muscle activation contribute meaningfully to continence mechanisms and erectile physiology.</p>
      <p>Conservative management strategies include pelvic floor physiotherapy, Kegel exercises, electrical stimulation, behavioral training, biofeedback, vaginal cones, medications, and lifestyle interventions. However, adherence to home exercise regimens is often poor, and traditional stimulation modalities may be uncomfortable or inadequate for inducing deep neuromuscular activation. Surgical intervention is effective in selected cases but is invasive and not universally acceptable.</p>
      <p>High-intensity targeted electromagnetic (HITEM) and related neuromuscular electromagnetic technologies have recently emerged as non-invasive rehabilitation platforms designed to induce supramaximal muscle contractions through rapidly changing electromagnetic fields. Electromagnetic induction can depolarize motor neurons and induce repetitive involuntary muscle contraction without requiring direct cutaneous electrical contact. Repeated supramaximal contractions may contribute to muscle hypertrophy, neuromuscular re-education, improved circulation, and connective tissue remodeling.</p>
      <p>The Heager GmbH Alfonse electromagnetic therapy system was developed as a multimodal rehabilitation platform incorporating three independent electromagnetic generators intended to target anatomically and functionally distinct muscle groups simultaneously or independently. The system concept includes:</p>
      <p>1. A pelvic floor-targeted generator intended to stimulate levator ani and pelvic support musculature.</p>
      <p>2. A cavernous/perineal-targeted generator intended to support perineal and erectile-associated musculature.</p>
      <p>3. An abdominal/core-targeted generator intended to support abdominal stabilization and lumbopelvic functional balance.</p>
      <p>The rationale for multimodal synchronized activation is based on the concept that continence, pelvic support, posture, sexual function, and lumbopelvic biomechanics are interdependent rather than isolated processes.</p>
      <p>In addition to clinical symptom assessment, modern rehabilitation technologies increasingly require objective biological and imaging validation. Ultrasound imaging permits visualization of pelvic floor movement, muscle thickness, and levator support. Histopathological and molecular analyses may provide insight into muscle fiber organization, angiogenic response, extracellular remodeling, and adaptive neuromuscular tissue response.</p>
      <p>This prospective multicenter study was therefore designed to evaluate the clinical effectiveness, sonographic findings, histopathological changes, immunohistochemical patterns, and short-term safety profile associated with multimodal electromagnetic therapy using the Heager GmbH Alfonse system.</p>
    </sec>
    <sec id="materials-and-methods">
      <label>2</label>
      <title>Materials and Methods</title>
      <sec id="study-design">
        <label>2.1</label>
        <title>Study Design</title>
        <p>This investigation was designed as a prospective, multicenter, exploratory clinical cohort study performed between January 2022 and March 2025 across urogynecology, rehabilitation medicine, pelvic floor therapy, and men’s health centers in South America.</p>
        <p>The study evaluated short-term and intermediate-term outcomes associated with multimodal electromagnetic neuromuscular stimulation therapy.</p>
      </sec>
      <sec id="ethical-approval-and-consent">
        <label>2.2</label>
        <title>Ethical Approval and Consent</title>
        <p>This study represents an observational clinical analysis performed during routine medical practice. All analyzed data were anonymized prior to scientific evaluation and publication. The study was conducted in accordance with generally accepted ethical standards for clinical research and patient confidentiality principles.</p>
      </sec>
      <sec id="study-population">
        <label>2.3</label>
        <title>Study Population</title>
        <p>A total of 100 adult participants were enrolled.</p>
      </sec>
      <sec id="female-cohort">
        <label>2.4</label>
        <title>Female Cohort</title>
        <p>Women presenting with:</p>
        <list list-type="bullet">
          <list-item>
            <p>stress urinary incontinence,</p>
          </list-item>
          <list-item>
            <p>mixed urinary symptoms,</p>
          </list-item>
          <list-item>
            <p>postpartum pelvic floor weakness,</p>
          </list-item>
          <list-item>
            <p>pelvic floor instability,</p>
          </list-item>
          <list-item>
            <p>chronic pelvic weakness,</p>
          </list-item>
          <list-item>
            <p>or mild pelvic support dysfunction.</p>
          </list-item>
        </list>
      </sec>
      <sec id="male-cohort">
        <label>2.5</label>
        <title>Male Cohort</title>
        <p>Men presenting with:</p>
        <list list-type="bullet">
          <list-item>
            <p>erectile dysfunction,</p>
          </list-item>
          <list-item>
            <p>pelvic floor weakness,</p>
          </list-item>
          <list-item>
            <p>perineal instability,</p>
          </list-item>
          <list-item>
            <p>or chronic pelvic dysfunction.</p>
          </list-item>
        </list>
      </sec>
      <sec id="musculoskeletal-cohort">
        <label>2.6</label>
        <title>Musculoskeletal Cohort</title>
        <p>Participants with:</p>
        <list list-type="bullet">
          <list-item>
            <p>chronic low back discomfort associated with poor core stability,</p>
          </list-item>
          <list-item>
            <p>abdominal muscular weakness,</p>
          </list-item>
          <list-item>
            <p>or lumbopelvic instability.</p>
          </list-item>
        </list>
      </sec>
      <sec id="inclusion-criteria">
        <label>2.7</label>
        <title>Inclusion Criteria</title>
        <p>Participants were eligible if they:</p>
        <p>1. Were aged 21–75 years.</p>
        <p>2. Had symptomatic pelvic floor dysfunction, urinary symptoms, erectile dysfunction, or core instability.</p>
        <p>3. Were medically stable.</p>
        <p>4. Were willing to complete the treatment schedule.</p>
        <p>5. Could complete questionnaires and follow-up.</p>
        <p>6. Provided written informed consent.</p>
      </sec>
      <sec id="exclusion-criteria">
        <label>2.8</label>
        <title>Exclusion Criteria</title>
        <p>Participants were excluded for:</p>
        <p>1. Pregnancy.</p>
        <p>2. Implanted pacemakers or neurostimulators.</p>
        <p>3. Metallic implants incompatible with electromagnetic therapy.</p>
        <p>4. Active pelvic malignancy.</p>
        <p>5. Uncontrolled neurologic disorders.</p>
        <p>6. Severe cardiac instability.</p>
        <p>7. Acute pelvic infection.</p>
        <p>8. Recent pelvic surgery (&lt;3 months).</p>
        <p>9. Uncontrolled seizure disorders.</p>
        <p>10. Severe uncontrolled psychiatric disease.</p>
      </sec>
    </sec>
    <sec id="device-description-and-electromagnetic-engineeri">
      <label>3</label>
      <title>Device Description and Electromagnetic Engineering</title>
      <p>The Heager GmbH Alfonse system is a chair-based multimodal electromagnetic rehabilitation platform incorporating three independent electromagnetic wave generators designed to stimulate anatomically distinct neuromuscular regions.</p>
      <sec id="generator-configuration">
        <label>3.1</label>
        <title>Generator Configuration</title>
      </sec>
      <sec id="generator-intended-anatomical-target-nominal-fie">
        <label>3.2</label>
        <title>Generator Intended Anatomical Target Nominal Field Capacity</title>
        <p>Generator A Pelvic floor musculature 3 Tesla</p>
        <p>Generator B Abdominal/core musculature 2.5 Tesla</p>
        <p>Generator C Cavernous/perineal musculature 1.5 Tesla</p>
        <p>The platform permits:</p>
        <list list-type="bullet">
          <list-item>
            <p>independent activation,</p>
          </list-item>
          <list-item>
            <p>synchronized multimodal stimulation,</p>
          </list-item>
          <list-item>
            <p>variable pulse sequencing,</p>
          </list-item>
          <list-item>
            <p>frequency modulation,</p>
          </list-item>
          <list-item>
            <p>and region-specific therapeutic programming.</p>
          </list-item>
        </list>
        <p>The system is designed to induce rapidly alternating electromagnetic fields capable of depolarizing motor neurons and inducing involuntary supramaximal muscle contractions.</p>
      </sec>
      <sec id="electrophysiological-rationale">
        <label>3.3</label>
        <title>Electrophysiological Rationale</title>
        <p>Electromagnetic induction therapy operates through rapidly changing magnetic fields that induce electric currents in excitable tissue according to Faraday’s law of induction.</p>
        <p>The induced current depolarizes motor neurons, generating repetitive muscle contractions that may exceed the intensity achievable through voluntary contraction alone.</p>
        <p>Potential physiological effects include:</p>
        <p>1. Neuromuscular re-education.</p>
        <p>2. Increased muscle recruitment.</p>
        <p>3. Improved pelvic support.</p>
        <p>4. Enhanced circulation.</p>
        <p>5. Increased local metabolic activity.</p>
        <p>6. Improved proprioceptive signaling.</p>
        <p>7. Muscular hypertrophy and strengthening.</p>
        <p>8. Enhanced vascular perfusion.</p>
        <p>9. Connective tissue remodeling.</p>
        <p>10. Functional support of continence mechanisms.</p>
        <p>In male patients, stimulation of perineal and cavernous-associated musculature may contribute to improved erectile support through enhanced pelvic floor contraction, improved vascular support, and neuromuscular recruitment.</p>
        <p>In women with urinary symptoms, strengthening of levator ani and periurethral support musculature may improve urethral closure dynamics and pelvic support.</p>
      </sec>
    </sec>
    <sec id="treatment-protocol">
      <label>4</label>
      <title>Treatment Protocol</title>
      <p>Participants underwent structured electromagnetic therapy sessions over 6–8 weeks.</p>
      <sec id="standard-protocol">
        <label>4.1</label>
        <title>Standard Protocol</title>
        <list list-type="bullet">
          <list-item>
            <p>2 sessions weekly.</p>
          </list-item>
          <list-item>
            <p>Session duration: 28–35 minutes.</p>
          </list-item>
          <list-item>
            <p>Progressive intensity escalation according to tolerance.</p>
          </list-item>
          <list-item>
            <p>Simultaneous or sequential generator activation depending on indication.</p>
          </list-item>
        </list>
      </sec>
      <sec id="pelvic-floor-protocol">
        <label>4.2</label>
        <title>Pelvic Floor Protocol</title>
        <p>Targeted pelvic floor stimulation using Generator A.</p>
      </sec>
      <sec id="erectile-dysfunction-protocol">
        <label>4.3</label>
        <title>Erectile Dysfunction Protocol</title>
        <p>Combined perineal/cavernous stimulation using Generator C with supportive core stabilization activation.</p>
      </sec>
      <sec id="core-rehabilitation-protocol">
        <label>4.4</label>
        <title>Core Rehabilitation Protocol</title>
        <p>Abdominal and lumbopelvic activation using Generator B.</p>
        <p>Treatment intensity was adjusted according to:</p>
        <list list-type="bullet">
          <list-item>
            <p>patient comfort,</p>
          </list-item>
          <list-item>
            <p>visible muscle contraction,</p>
          </list-item>
          <list-item>
            <p>tolerance,</p>
          </list-item>
          <list-item>
            <p>and therapeutic response.</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="outcome-measures">
      <label>5</label>
      <title>Outcome Measures</title>
      <sec id="primary-clinical-endpoints">
        <label>5.1</label>
        <title>Primary Clinical Endpoints</title>
      </sec>
      <sec id="urinary-symptoms">
        <label>5.2</label>
        <title>Urinary Symptoms</title>
        <list list-type="bullet">
          <list-item>
            <p>ICIQ-SF.</p>
          </list-item>
          <list-item>
            <p>Pad testing.</p>
          </list-item>
          <list-item>
            <p>Pelvic floor strength grading.</p>
          </list-item>
        </list>
      </sec>
      <sec id="erectile-dysfunction">
        <label>5.3</label>
        <title>Erectile Dysfunction</title>
        <list list-type="bullet">
          <list-item>
            <p>IIEF-5.</p>
          </list-item>
          <list-item>
            <p>Patient-reported erection quality.</p>
          </list-item>
          <list-item>
            <p>Sexual confidence scoring.</p>
          </list-item>
        </list>
      </sec>
      <sec id="musculoskeletal-outcomes">
        <label>5.4</label>
        <title>Musculoskeletal Outcomes</title>
        <list list-type="bullet">
          <list-item>
            <p>Core stability assessment.</p>
          </list-item>
          <list-item>
            <p>Lower back discomfort scoring.</p>
          </list-item>
          <list-item>
            <p>Functional movement assessment.</p>
          </list-item>
        </list>
      </sec>
      <sec id="secondary-outcomes">
        <label>5.5</label>
        <title>Secondary Outcomes</title>
        <p>1. Quality-of-life improvement.</p>
        <p>2. Patient global satisfaction.</p>
        <p>3. Sonographic muscle assessment.</p>
        <p>4. Histopathological remodeling.</p>
        <p>5. Molecular marker changes.</p>
        <p>6. Adverse event monitoring.</p>
      </sec>
      <sec id="sonographic-assessment">
        <label>5.6</label>
        <title>Sonographic Assessment</title>
        <p>Transperineal and pelvic ultrasound imaging was performed before and after treatment.</p>
        <p>Imaging assessment included:</p>
        <list list-type="bullet">
          <list-item>
            <p>pelvic floor muscle thickness,</p>
          </list-item>
          <list-item>
            <p>levator support,</p>
          </list-item>
          <list-item>
            <p>muscle density,</p>
          </list-item>
          <list-item>
            <p>dynamic contraction assessment,</p>
          </list-item>
          <list-item>
            <p>and structural organization.</p>
          </list-item>
        </list>
        <p>Selected participants underwent Doppler evaluation for vascular perfusion assessment.</p>
        <p>Representative imaging demonstrated:</p>
        <list list-type="bullet">
          <list-item>
            <p>improved muscular organization,</p>
          </list-item>
          <list-item>
            <p>increased echogenic consistency,</p>
          </list-item>
          <list-item>
            <p>and enhanced functional contraction dynamics.</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="histopathological-and-molecular-analysis">
      <label>6</label>
      <title>Histopathological and Molecular Analysis</title>
      <p>A subset of consenting participants underwent exploratory tissue evaluation.</p>
      <sec id="histopathological-assessment">
        <label>6.1</label>
        <title>Histopathological Assessment</title>
      </sec>
      <sec id="staining-included">
        <label>6.2</label>
        <title>Staining included</title>
        <list list-type="bullet">
          <list-item>
            <p>Hematoxylin and eosin (H&amp;E),</p>
          </list-item>
          <list-item>
            <p>Masson’s trichrome,</p>
          </list-item>
          <list-item>
            <p>connective tissue evaluation.</p>
          </list-item>
        </list>
      </sec>
      <sec id="observed-findings-included">
        <label>6.3</label>
        <title>Observed findings included</title>
        <list list-type="bullet">
          <list-item>
            <p>improved muscle fiber alignment,</p>
          </list-item>
          <list-item>
            <p>reduced interstitial disorganization,</p>
          </list-item>
          <list-item>
            <p>improved stromal organization,</p>
          </list-item>
          <list-item>
            <p>and reduced degenerative appearance.</p>
          </list-item>
        </list>
      </sec>
      <sec id="immunohistochemical-analysis">
        <label>6.4</label>
        <title>Immunohistochemical Analysis</title>
        <p>Markers evaluated included:</p>
      </sec>
      <sec id="sma-alpha-smooth-muscle-actin">
        <label>6.5</label>
        <title>α-SMA (Alpha Smooth Muscle Actin)</title>
        <p>Marker associated with smooth muscle integrity and contractile tissue activity.</p>
      </sec>
      <sec id="vegf-vascular-endothelial-growth-factor">
        <label>6.6</label>
        <title>VEGF (Vascular Endothelial Growth Factor)</title>
        <p>Marker associated with angiogenesis and vascular remodeling.</p>
        <p>Post-treatment tissue demonstrated increased α-SMA and VEGF expression compared with baseline samples.</p>
      </sec>
      <sec id="statistical-analysis">
        <label>6.7</label>
        <title>Statistical Analysis</title>
        <p>Continuous variables were expressed as mean ± standard deviation.</p>
        <p>Paired comparisons between baseline and follow-up were analyzed using:</p>
        <list list-type="bullet">
          <list-item>
            <p>paired t-tests,</p>
          </list-item>
          <list-item>
            <p>Wilcoxon signed-rank tests,</p>
          </list-item>
          <list-item>
            <p>• and repeated measures analysis where appropriate.</p>
          </list-item>
        </list>
        <p>Categorical variables were analyzed using chi-square or Fisher’s exact testing.</p>
        <p>A p-value &lt;0.05 was considered statistically significant.</p>
      </sec>
    </sec>
    <sec id="results">
      <label>7</label>
      <title>Results</title>
      <sec id="participant-completion">
        <label>7.1</label>
        <title>Participant Completion</title>
        <p>Most participants completed the full treatment protocol and follow-up schedule.</p>
      </sec>
      <sec id="urinary-symptom-outcomes">
        <label>7.2</label>
        <title>Urinary Symptom Outcomes</title>
        <p>Patients with stress urinary incontinence demonstrated significant reduction in urinary leakage frequency and symptom burden.</p>
        <p>Mean ICIQ-SF scores improved significantly after treatment.</p>
        <p>Many participants reported:</p>
        <list list-type="bullet">
          <list-item>
            <p>improved pelvic support sensation,</p>
          </list-item>
          <list-item>
            <p>reduced urgency episodes,</p>
          </list-item>
          <list-item>
            <p>and improved confidence during physical activity.</p>
          </list-item>
        </list>
      </sec>
      <sec id="erectile-dysfunction-outcomes">
        <label>7.3</label>
        <title>Erectile Dysfunction Outcomes</title>
        <p>Male participants demonstrated clinically meaningful improvement in IIEF-5 scores.</p>
        <p>Participants reported:</p>
        <list list-type="bullet">
          <list-item>
            <p>improved erection rigidity,</p>
          </list-item>
          <list-item>
            <p>improved maintenance,</p>
          </list-item>
          <list-item>
            <p>increased confidence,</p>
          </list-item>
          <list-item>
            <p>and improved pelvic muscular control.</p>
          </list-item>
        </list>
      </sec>
      <sec id="core-rehabilitation-outcomes">
        <label>7.4</label>
        <title>Core Rehabilitation Outcomes</title>
        <p>Participants with core instability and lower back discomfort demonstrated:</p>
        <list list-type="bullet">
          <list-item>
            <p>improved abdominal tone,</p>
          </list-item>
          <list-item>
            <p>improved postural stability,</p>
          </list-item>
          <list-item>
            <p>improved pelvic control,</p>
          </list-item>
          <list-item>
            <p>and reduced chronic lower back discomfort.</p>
          </list-item>
        </list>
      </sec>
      <sec id="sonographic-findings">
        <label>7.5</label>
        <title>Sonographic Findings</title>
        <p>Ultrasound assessment demonstrated:</p>
        <list list-type="bullet">
          <list-item>
            <p>increased pelvic floor muscular density,</p>
          </list-item>
          <list-item>
            <p>improved contraction dynamics,</p>
          </list-item>
          <list-item>
            <p>increased structural organization,</p>
          </list-item>
          <list-item>
            <p>and improved levator support.</p>
          </list-item>
        </list>
        <p>No imaging evidence of structural injury or tissue destruction was observed.</p>
      </sec>
      <sec id="histopathological-findings">
        <label>7.6</label>
        <title>Histopathological Findings</title>
        <p>Histological evaluation demonstrated:</p>
        <list list-type="bullet">
          <list-item>
            <p>improved muscle fiber alignment,</p>
          </list-item>
          <list-item>
            <p>reduced interstitial irregularity,</p>
          </list-item>
          <list-item>
            <p>improved connective tissue organization,</p>
          </list-item>
          <list-item>
            <p>and reduced degenerative changes.</p>
          </list-item>
        </list>
        <p>Masson’s trichrome staining demonstrated more organized connective tissue architecture after treatment.</p>
      </sec>
      <sec id="immunohistochemical-findings">
        <label>7.7</label>
        <title>Immunohistochemical Findings</title>
        <p>Post-treatment tissue demonstrated:</p>
        <list list-type="bullet">
          <list-item>
            <p>increased α-SMA expression,</p>
          </list-item>
          <list-item>
            <p>increased VEGF signaling,</p>
          </list-item>
          <list-item>
            <p>improved vascular density,</p>
          </list-item>
          <list-item>
            <p>and evidence of adaptive tissue remodeling.</p>
          </list-item>
        </list>
        <p>These findings support the hypothesis that repetitive electromagnetic neuromuscular activation may induce biological adaptation beyond temporary muscular contraction.</p>
      </sec>
      <sec id="safety-and-tolerability">
        <label>7.8</label>
        <title>Safety and Tolerability</title>
        <p>No serious device-related adverse events were observed.</p>
        <p>The most common adverse effects included:</p>
        <list list-type="bullet">
          <list-item>
            <p>mild transient muscle soreness,</p>
          </list-item>
          <list-item>
            <p>temporary fatigue sensation,</p>
          </list-item>
          <list-item>
            <p>and mild post-treatment muscular tightness.</p>
          </list-item>
        </list>
        <p>No participant discontinued therapy due to adverse events.</p>
        <p>No cases of:</p>
        <list list-type="bullet">
          <list-item>
            <p>burns,</p>
          </list-item>
          <list-item>
            <p>neurologic injury,</p>
          </list-item>
          <list-item>
            <p>tissue destruction,</p>
          </list-item>
          <list-item>
            <p>urinary retention,</p>
          </list-item>
          <list-item>
            <p>or major cardiovascular complications were observed.</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="discussion">
      <label>8</label>
      <title>Discussion</title>
      <p>This prospective multicenter cohort study suggests that multimodal electromagnetic rehabilitation therapy using the Heager GmbH Alfonse system may provide clinically meaningful improvements in urinary symptoms, pelvic support function, erectile function, and core muscular stability.</p>
      <p>The observed sonographic, histopathological, and molecular findings strengthen the biological plausibility of the therapeutic response.</p>
      <p>Unlike passive therapies, electromagnetic neuromuscular stimulation induces involuntary supramaximal contractions that may recruit deeper muscular structures not consistently activated during voluntary exercise.</p>
      <p>The multimodal design of the Heager GmbH Alfonse system represents a notable engineering distinction. Rather than focusing on a single muscular target, the platform attempts synchronized stimulation of:</p>
      <list list-type="bullet">
        <list-item>
          <p>pelvic floor support structures,</p>
        </list-item>
        <list-item>
          <p>cavernous/perineal musculature,</p>
        </list-item>
        <list-item>
          <p>and abdominal stabilizing musculature.</p>
        </list-item>
      </list>
      <p>This approach aligns with modern understanding of lumbopelvic biomechanics, where continence, posture, pelvic support, sexual function, and core stabilization interact as integrated neuromuscular systems.</p>
      <p>The increase in α-SMA expression suggests adaptive smooth muscle or contractile tissue response. VEGF upregulation suggests vascular remodeling and improved tissue perfusion.</p>
      <p>The ultrasound findings are particularly important because pelvic floor imaging provides objective evidence of functional muscular adaptation beyond subjective symptom reporting.</p>
      <p>The erectile dysfunction findings are also notable because pelvic floor rehabilitation has increasingly been recognized as a supportive therapeutic strategy in male sexual medicine.</p>
      <p>Compared with traditional electrical stimulation:</p>
      <list list-type="bullet">
        <list-item>
          <p>electromagnetic stimulation avoids direct skin electrodes,</p>
        </list-item>
        <list-item>
          <p>may penetrate deeper tissue,</p>
        </list-item>
        <list-item>
          <p>and may improve patient comfort and adherence.</p>
        </list-item>
      </list>
      <p>However, the study must be interpreted cautiously.</p>
      <sec id="limitations">
        <label>8.1</label>
        <title>Limitations</title>
        <p>Several limitations must be acknowledged:</p>
        <p>1. Single-arm study design.</p>
        <p>2. Lack of sham control.</p>
        <p>3. Short-term follow-up.</p>
        <p>4. Limited objective electrophysiological analysis.</p>
        <p>5. Heterogeneous patient population.</p>
        <p>6. Limited long-term durability assessment.</p>
        <p>7. Histological analysis performed only in selected participants.</p>
        <p>8. Absence of randomized comparison with pelvic floor physiotherapy or other HITEM platforms.</p>
        <p>9. Potential placebo contribution.</p>
        <p>10. Limited standardization of electromagnetic dosimetry reporting.</p>
        <p>Future randomized controlled trials should include:</p>
        <list list-type="bullet">
          <list-item>
            <p>EMG analysis,</p>
          </list-item>
          <list-item>
            <p>urodynamics,</p>
          </list-item>
          <list-item>
            <p>MRI muscular evaluation,</p>
          </list-item>
          <list-item>
            <p>quantitative ultrasound,</p>
          </list-item>
          <list-item>
            <p>standardized erectile function testing,</p>
          </list-item>
          <list-item>
            <p>and long-term follow-up.</p>
          </list-item>
        </list>
      </sec>
    </sec>
    <sec id="conclusion">
      <label>9</label>
      <title>Conclusion</title>
      <p>The Heager GmbH Alfonse multimodal electromagnetic rehabilitation system demonstrated encouraging clinical, sonographic, histopathological, and molecular findings in participants with pelvic floor dysfunction, urinary symptoms, erectile dysfunction, and core muscular instability.</p>
      <p>The integration of independent electromagnetic generators targeting pelvic floor, cavernous/perineal, and abdominal musculature represents a novel multimodal rehabilitation concept.</p>
      <p>Short-term treatment was well tolerated and associated with improvements in continence-related symptoms, pelvic support sensation, erectile function, and muscular organization.</p>
      <p>Further sham-controlled randomized studies with objective electrophysiological and imaging validation are warranted.</p>
      <fig id="figure-1">
        <label>Figure 1</label>
        <caption>
          <p>Heager GmbH Alfonse multimodal electromagnetic therapy chair system.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-1.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <fig id="figure-2">
        <label>Figure 2</label>
        <caption>
          <p>Molecular staining shows -SMA and VEGF expression before and after therapy.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-2.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <fig id="figure-3">
        <label>Figure 3</label>
        <caption>
          <p>Transperineal sonographic imaging of pelvic floor musculature.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-3.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <fig id="figure-4">
        <label>Figure 4</label>
        <caption>
          <p>IIEF-5 score improvement graph.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-4.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <fig id="figure-5">
        <label>Figure 5</label>
        <caption>
          <p>Pelvic floor contraction mechanism diagram.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-5.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <fig id="figure-6">
        <label>Figure 6</label>
        <caption>
          <p>Electromagnetic induction and neuromuscular depolarization schematic.</p>
        </caption>
        <graphic xlink:href="https://directivepublications.org/storage/ftv2/985-c3cc4b3d7536cb400423/fig-figure-6.png" mimetype="image" mime-subtype="png"/>
      </fig>
      <table-wrap id="table-1">
        <label>Table 1</label>
        <caption>
          <p>Recommended Clinical Parameters — Alfonse Electromagnetic Therapy System.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"><bold>Clinical Indication</bold></th>
              <th scope="col"><bold>Generator Configuration</bold></th>
              <th scope="col"><bold>Intensity Range</bold></th>
              <th scope="col"><bold>Session Duration</bold></th>
              <th scope="col"><bold>Sessions</bold></th>
              <th scope="col"><bold>Clinical Goal</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row">Stress urinary incontinence</th>
              <td>Pelvic floor generator dominant (3 T)</td>
              <td>40–90% intensity</td>
              <td>28–35 min</td>
              <td>6–10</td>
              <td>Pelvic floor strengthening</td>
            </tr>
            <tr>
              <th scope="row">Pelvic floor rehabilitation</th>
              <td>3 T pelvic generator + 2.5 T core support</td>
              <td>50–95%</td>
              <td>30–40 min</td>
              <td>6–12</td>
              <td>Neuromuscular re-education</td>
            </tr>
            <tr>
              <th scope="row">Erectile dysfunction</th>
              <td>1.5 T cavernous/perineal generator</td>
              <td>40–85%</td>
              <td>25–35 min</td>
              <td>6–10</td>
              <td>Cavernous muscular activation</td>
            </tr>
            <tr>
              <th scope="row">Postpartum pelvic weakness</th>
              <td>Combined pelvic + abdominal mode</td>
              <td>35–80%</td>
              <td>30–40 min</td>
              <td>8–12</td>
              <td>Pelvic stability restoration</td>
            </tr>
            <tr>
              <th scope="row">Core strengthening</th>
              <td>2.5 T abdominal generator dominant</td>
              <td>50–100%</td>
              <td>30–45 min</td>
              <td>6–12</td>
              <td>Abdominal hypertrophy and stabilization</td>
            </tr>
            <tr>
              <th scope="row">Chronic lower back instability</th>
              <td>Core + pelvic synchronized mode</td>
              <td>50–90%</td>
              <td>35–45 min</td>
              <td>8–12</td>
              <td>Lumbopelvic stabilization</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <table-wrap id="table-2">
        <label>Table 2</label>
        <caption>
          <p>Technical Characteristics — Alfonse Electromagnetic Platform.</p>
        </caption>
        <table>
          <thead>
            <tr>
              <th scope="col"><bold>Parameter</bold></th>
              <th scope="col"><bold>Technical Description</bold></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <th scope="row">Platform Type</th>
              <td>Multimodal electromagnetic rehabilitation system</td>
            </tr>
            <tr>
              <th scope="row">Electromagnetic Generators</th>
              <td>3 independent generators</td>
            </tr>
            <tr>
              <th scope="row">Generator A</th>
              <td>3 Tesla pelvic floor stimulation</td>
            </tr>
            <tr>
              <th scope="row">Generator B</th>
              <td>2.5 Tesla abdominal/core stimulation</td>
            </tr>
            <tr>
              <th scope="row">Generator C</th>
              <td>1.5 Tesla cavernous/perineal stimulation</td>
            </tr>
            <tr>
              <th scope="row">Combined Therapeutic Architecture</th>
              <td>Simultaneous or independent generator activation</td>
            </tr>
            <tr>
              <th scope="row">Intended Biological Action</th>
              <td>Supramaximal neuromuscular contraction</td>
            </tr>
            <tr>
              <th scope="row">Target Structures</th>
              <td>Pelvic floor, core musculature, cavernous/perineal musculature</td>
            </tr>
            <tr>
              <th scope="row">Treatment Method</th>
              <td>Noninvasive electromagnetic neuromuscular stimulation</td>
            </tr>
            <tr>
              <th scope="row">Energy Delivery</th>
              <td>Rapid alternating electromagnetic induction</td>
            </tr>
            <tr>
              <th scope="row">Clinical Applications</th>
              <td>Pelvic rehabilitation, ED support, continence therapy, core strengthening</td>
            </tr>
            <tr>
              <th scope="row">Cooling Requirement</th>
              <td>Not typically required</td>
            </tr>
            <tr>
              <th scope="row">Patient Interface</th>
              <td>Chair-based seated therapy system</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
  </body>
  <back>
    <ref-list>
      <title>References</title>
      <ref id="ref-1">
        <label>1</label>
        <mixed-citation>Jundt K, Peschers U, Kentenich H. The investigation and treatment of female pelvic floor dysfunction. Dtsch Ärztebl Int. 2015;112(33–34):564–574.</mixed-citation>
      </ref>
      <ref id="ref-2">
        <label>2</label>
        <mixed-citation>Aoki Y, Brown HW, Brubaker L, et al. Urinary incontinence in women. Nat Rev Dis Primers. 2017;3:17042.</mixed-citation>
      </ref>
      <ref id="ref-3">
        <label>3</label>
        <mixed-citation>Lim R, Liong ML, Leong WS, et al. Pulsed magnetic stimulation for stress urinary incontinence: 1-year follow-up results. J Urol. 2017;197(5):1302–1308.</mixed-citation>
      </ref>
      <ref id="ref-4">
        <label>4</label>
        <mixed-citation>Yokoyama T, Fujita O, Nishiguchi J, et al. Extracorporeal magnetic innervation treatment for urinary incontinence. Int J Urol. 2004;11(8):602–606.</mixed-citation>
      </ref>
      <ref id="ref-5">
        <label>5</label>
        <mixed-citation>Samuels JB, Pezzella A, Berenholz J, et al. Safety and efficacy of non-invasive high-intensity targeted electromagnetic field treatment. Lasers Surg Med. 2019;51(9):760–766.</mixed-citation>
      </ref>
      <ref id="ref-6">
        <label>6</label>
        <mixed-citation>Dietz HP. Pelvic floor ultrasound: a review. Am J Obstet Gynecol. 2010;202(4):321–334.</mixed-citation>
      </ref>
      <ref id="ref-7">
        <label>7</label>
        <mixed-citation>Bø K, Berghmans B, Mørkved S, et al. Evidence-Based Physical Therapy for the Pelvic Floor. Churchill Livingstone; 2015.</mixed-citation>
      </ref>
      <ref id="ref-8">
        <label>8</label>
        <mixed-citation>Glazer HI, Romanzi L, Polaneczky M. Pelvic floor muscle surface electromyography. J Reprod Med. 1999;44(9):779–782.</mixed-citation>
      </ref>
      <ref id="ref-9">
        <label>9</label>
        <mixed-citation>Newman DK. Pelvic floor muscle rehabilitation using biofeedback. Urol Nurs. 2014;34(4):193–202.</mixed-citation>
      </ref>
      <ref id="ref-10">
        <label>10</label>
        <mixed-citation>Castro RA, Arruda RM, Zanetti MRD, et al. Randomized controlled trial of pelvic floor training and electrical stimulation. Clinics. 2008;63(4):465–472.</mixed-citation>
      </ref>
      <ref id="ref-11">
        <label>11</label>
        <mixed-citation>Yang S, Sang W, Feng J, et al. Pelvic nerve electrophysiology and tissue function rehabilitation study. J Clin Nurs. 2017;26(23–24):4537–4547.</mixed-citation>
      </ref>
      <ref id="ref-12">
        <label>12</label>
        <mixed-citation>Dietz HP, Shek KL. Levator avulsion and pelvic floor ultrasound assessment. Ultrasound Obstet Gynecol. 2008;32(7):941–945.</mixed-citation>
      </ref>
      <ref id="ref-13">
        <label>13</label>
        <mixed-citation>Prodanovic M, Malešević J, Filipovic M, et al. Numerical simulation of energy distribution in biological tissues during electrical stimulation. Serbian J Electr Eng. 2013;10:165–173.</mixed-citation>
      </ref>
      <ref id="ref-14">
        <label>14</label>
        <mixed-citation>Fowler CJ, Panicker JN, Emmanuel A. Pelvic Organ Dysfunction in Neurological Disease. Cambridge University Press; 2010.</mixed-citation>
      </ref>
      <ref id="ref-15">
        <label>15</label>
        <mixed-citation>Bø K, Talseth T, Holme I. Pelvic floor exercise and stimulation randomized trial. BMJ. 1999;318(7182):487–493.</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
